01.03.2010 • NewsCatalysis & CatalystsEvonikH.C. Starck

Evonik Acquires Catalyst Business From H.C. Starck

Evonik Industries has acquired the catalyst business of H.C. Starck GmbH based in Goslar, Germany. The know-how and technology relating to the production and use of Amperkat catalysts have therefore been transferred to Evonik. Following a transition phase, Evonik will produce these catalysts in Hanau, Germany. The Amperkat brand comprises activated metal catalysts-known as skeletal catalysts and customized supported catalysts. The Amperkat business focuses principally on activated nickel catalysts, which are used in the pharmaceuticals and food industries and in fine and industrial chemicals, for example, for producing selective pharmaceutical active substances, sweeteners, and starting materials for polyurethanes for the building materials and automotive sectors.

Evonik is a global leader in producing activated metal catalysts and precious metal powder catalysts. Both product groups are used in similar market segments, but their activity and selectivity differ enormously. The acquisition of Amperkat catalysts complements Evonik's present range of products and customized solutions.

 

Company

Logo:

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read